The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001238369p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
1/09/2026
Date registered
Help: Date registered
13/10/2026
Date last updated
Help: Date last updated
13/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Double Blind placebo-controlled RCT of High Efficiency Particulate Air (HEPA) filters to assess efficacy for reducing exacerbations in adults with moderate to severe chronic obstructive pulmonary disease (COPD)
Scientific title
Investigating A Novel Way to reduce the Burden of chronic obstructive pulmonary disease (COPD) exacerbations in adults with moderate to severe COPD using Hepa filters. A double-blind randomised placebo-controlled trial (NEWBREATH)
Additional trial identifiers [1] 317972 0
Nil
Universal Trial Number (UTN)
Trial acronym
NEWBREATH
Related trial records

Health condition
Health condition(s) studied:
Chronic obstructive pulmonary disease 342941 0
Condition category
Condition code
Respiratory 339060 339060 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants allocated to the intervention group will receive two HEPA filter air purifiers placed at home for 12 months. One will be placed in bedroom, the other will be placed in the living area. We will use Hefil HEPA filter manufactured from Shanghai Heyi Purification Equipment Manufacturing Co. Ltd. The device is designed to remove airborne particles and allergens and is suitable for cleaning the air in a standard-sized room. Participants will be instructed to operate the filters daily(living room ) and nightly(bedroom)over a 12 month period

The intervention will be delivered to participants’ homes by trained research staff during a scheduled home visit, which will include installation, demonstration of device use, and provision of written instructions. Participants will also be given contact details for technical support if required.

To monitor adherence, participants will complete adherence check questionnaires at Day 7 and Day 14 after installation, and subsequently at monthly intervals throughout the 12-month study period. In addition, each HEPA unit contains an internal meter that records operational time and usage.

Temporary non-use or discontinuation of the intervention is discouraged, but if required, participants will be instructed to notify study staff immediately. All interruptions and reasons for non-use will be documented in the Incident Report Form.

The intervention will be discontinued if a participant withdraws from the study, if continued use poses a safety risk, or if protocol violations occur that may compromise participant safety.
Intervention code [1] 334837 0
Prevention
Description of the comparator or control
Participants randomised to the control group will receive an identical-looking air purifier with the internal HEPA and carbon filters removed. The placebo filter will operate with similar noise, airflow, and appearance to maintain participant and investigator blinding.
Like the intervention group, the placebo filter will be installed and demonstrated by trained research staff during a home visit, and participants will be instructed to use it continuously for 12 months.
Control group
Placebo

Outcomes
Primary outcome [1] 346299 0
COPD exacerbation rate over 12 months
Timepoint [1] 346299 0
Baseline to 12 months post-randomisation (annualised COPD exacerbation rate)
Secondary outcome [1] 465565 0
Change in Functional Outcomes of Sleep Questionnaire (FOSQ-10) total score
Timepoint [1] 465565 0
Baseline and 12 months post-randomisation
Secondary outcome [2] 467241 0
Change in Pittsburgh Sleep Quality Index (PSQI) total score
Timepoint [2] 467241 0
Baseline and 12 months post-randomisation
Secondary outcome [3] 467242 0
Change in respiratory symptom questionnaire (RSQ) scores
Timepoint [3] 467242 0
Monthly from baseline to 12 months post-randomisation
Secondary outcome [4] 467244 0
General practitioner (GP) visits
Timepoint [4] 467244 0
Baseline and monthly thereafter until 12 months.
Secondary outcome [5] 467246 0
Forced expiratory volume in 1 second (FEV1)
Timepoint [5] 467246 0
Baseline, 6 months, and 12 months post-randomisation
Secondary outcome [6] 467247 0
Airway inflammation
Timepoint [6] 467247 0
Baseline, 6 months, and 12 months post-randomisation
Secondary outcome [7] 467248 0
Change in overall quality of life
Timepoint [7] 467248 0
Baseline and 12 months post-randomisation
Secondary outcome [8] 467249 0
Change in COPD symptom burden
Timepoint [8] 467249 0
Baseline and 12 months post-randomisation
Secondary outcome [9] 467253 0
Change in disease-specific respiratory health-related quality of life
Timepoint [9] 467253 0
Baseline and 12 months post-randomisation
Secondary outcome [10] 467254 0
Change in total immunoglobulin E (IgE)
Timepoint [10] 467254 0
Baseline and 12 months post-randomisation
Secondary outcome [11] 468703 0
Number of emergency department (ED) presentations
Timepoint [11] 468703 0
Baseline and monthly thereafter until 12 months.
Secondary outcome [12] 468704 0
Number of hospital admissions
Timepoint [12] 468704 0
Baseline and monthly thereafter until 12 months.
Secondary outcome [13] 468705 0
Medication use
Timepoint [13] 468705 0
Baseline and monthly thereafter until 12 months.
Secondary outcome [14] 468706 0
Forced vital capacity (FVC)
Timepoint [14] 468706 0
Baseline, 6 months and 12 months.
Secondary outcome [15] 468707 0
Change in allergen-specific immunoglobulin E (IgE)
Timepoint [15] 468707 0
Baseline, 6 months and 12 months.
Secondary outcome [16] 468708 0
Change in eosinophil count
Timepoint [16] 468708 0
Baseline, 6 months and 12 months.

Eligibility
Key inclusion criteria
1)Adults from the general population with a diagnosis of COPD
2)Post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80% predicted
3)At least 1 hospitalisation or at least 2 moderate exacerbations in the past 12 months
4)Individual living in Melbourne
5)Willing to have three home visits over 12months
6)Willing to use the HEPA filter continuously throughout the study period
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Significant comorbidities that interfere with participation (e.g. pulmonary fibrosis, lung cancer).
Enrolled in another interventional respiratory trial. Other significant cardio/ortho/neurological or other morbidities.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be maintained using a centralised REDCap randomisation module. The allocation sequence will be generated by an independent statistician and concealed from study personnel involved in participant recruitment and enrolment until randomisation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random sequence
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322517 0
Government body
Name [1] 322517 0
National Health and Medical Research Council (NHMRC) MRFF Early to Mid-Career Researchers Grant
Country [1] 322517 0
Australia
Primary sponsor type
University
Name
University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 325438 0
None
Name [1] 325438 0
Address [1] 325438 0
Country [1] 325438 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 321002 0
Science, Technology, Engineering, Mathematics and Medicine (STEMM 1)- Greater Than Low Risk (GTLR) committee
Ethics committee address [1] 321002 0
Ethics committee country [1] 321002 0
Australia
Date submitted for ethics approval [1] 321002 0
01/11/2026
Approval date [1] 321002 0
Ethics approval number [1] 321002 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152326 0
Dr Xin Dai
Address 152326 0
Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Vic 3053
Country 152326 0
Australia
Phone 152326 0
+61 3 8344 4565
Fax 152326 0
Email 152326 0
Contact person for public queries
Name 152327 0
Xin Dai
Address 152327 0
Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Vic 3053
Country 152327 0
Australia
Phone 152327 0
+61 3 8344 4565
Fax 152327 0
Email 152327 0
Contact person for scientific queries
Name 152328 0
Caroline Lodge
Address 152328 0
Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Vic 3053
Country 152328 0
Australia
Phone 152328 0
+61 390353447
Fax 152328 0
Email 152328 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Study data will not be shared beyond the duration of the trial. Primary results will be disseminated through peer-reviewed publications and conference presentations, following CONSORT guidelines. De-identified, aggregated data may be included in publications, but individual-level datasets will not be made available for secondary use or shared externally.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.